476 related articles for article (PubMed ID: 15100172)
21. Determination of drug interactions occurring with the metabolic pathways of irinotecan.
Charasson V; Haaz MC; Robert J
Drug Metab Dispos; 2002 Jun; 30(6):731-3. PubMed ID: 12019202
[TBL] [Abstract][Full Text] [Related]
22. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.
Xu G; Zhang W; Ma MK; McLeod HL
Clin Cancer Res; 2002 Aug; 8(8):2605-11. PubMed ID: 12171891
[TBL] [Abstract][Full Text] [Related]
23. Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin.
Hatfield MJ; Tsurkan L; Hyatt JL; Yu X; Edwards CC; Hicks LD; Wadkins RM; Potter PM
Br J Pharmacol; 2010 Aug; 160(8):1916-28. PubMed ID: 20649590
[TBL] [Abstract][Full Text] [Related]
24. Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application.
Yoon KJ; Hyatt JL; Morton CL; Lee RE; Potter PM; Danks MK
Mol Cancer Ther; 2004 Aug; 3(8):903-9. PubMed ID: 15299073
[TBL] [Abstract][Full Text] [Related]
25. Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.
Yoon KJ; Krull EJ; Morton CL; Bornmann WG; Lee RE; Potter PM; Danks MK
Mol Cancer Ther; 2003 Nov; 2(11):1171-81. PubMed ID: 14617791
[TBL] [Abstract][Full Text] [Related]
26. Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease.
d'Esposito F; Nebot N; Edwards RJ; Murray M
Br J Clin Pharmacol; 2010 Sep; 70(3):400-8. PubMed ID: 20716241
[TBL] [Abstract][Full Text] [Related]
27. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase.
Rivory LP; Bowles MR; Robert J; Pond SM
Biochem Pharmacol; 1996 Oct; 52(7):1103-11. PubMed ID: 8831730
[TBL] [Abstract][Full Text] [Related]
28. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy.
Danks MK; Morton CL; Krull EJ; Cheshire PJ; Richmond LB; Naeve CW; Pawlik CA; Houghton PJ; Potter PM
Clin Cancer Res; 1999 Apr; 5(4):917-24. PubMed ID: 10213229
[TBL] [Abstract][Full Text] [Related]
29. An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11.
Wierdl M; Tsurkan L; Hyatt JL; Edwards CC; Hatfield MJ; Morton CL; Houghton PJ; Danks MK; Redinbo MR; Potter PM
Cancer Gene Ther; 2008 Mar; 15(3):183-92. PubMed ID: 18188187
[TBL] [Abstract][Full Text] [Related]
30. The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action.
Harel M; Hyatt JL; Brumshtein B; Morton CL; Yoon KJ; Wadkins RM; Silman I; Sussman JL; Potter PM
Mol Pharmacol; 2005 Jun; 67(6):1874-81. PubMed ID: 15772291
[TBL] [Abstract][Full Text] [Related]
31. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions.
Slatter JG; Su P; Sams JP; Schaaf LJ; Wienkers LC
Drug Metab Dispos; 1997 Oct; 25(10):1157-64. PubMed ID: 9321519
[TBL] [Abstract][Full Text] [Related]
32. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase.
Wierdl M; Morton CL; Weeks JK; Danks MK; Harris LC; Potter PM
Cancer Res; 2001 Jul; 61(13):5078-82. PubMed ID: 11431344
[TBL] [Abstract][Full Text] [Related]
33. Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes.
Haaz MC; Riché C; Rivory LP; Robert J
Drug Metab Dispos; 1998 Aug; 26(8):769-74. PubMed ID: 9698291
[TBL] [Abstract][Full Text] [Related]
34. Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells.
Wu MH; Yan B; Humerickhouse R; Dolan ME
Clin Cancer Res; 2002 Aug; 8(8):2696-700. PubMed ID: 12171903
[TBL] [Abstract][Full Text] [Related]
35. Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) toxicity.
Hicks LD; Hyatt JL; Stoddard S; Tsurkan L; Edwards CC; Wadkins RM; Potter PM
J Med Chem; 2009 Jun; 52(12):3742-52. PubMed ID: 19534556
[TBL] [Abstract][Full Text] [Related]
36. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11).
Potter PM; Pawlik CA; Morton CL; Naeve CW; Danks MK
Cancer Res; 1998 Jun; 58(12):2646-51. PubMed ID: 9635592
[TBL] [Abstract][Full Text] [Related]
37. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
Yokokawa A; Kaneko S; Endo S; Minowa Y; Ayukawa H; Hirano R; Nagashima F; Naruge D; Okano N; Kobayashi T; Kawai K; Furuse J; Furuta T; Shibasaki H
Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):317-324. PubMed ID: 33619631
[TBL] [Abstract][Full Text] [Related]
38. Structural insights into catalytical capability for CPT11 hydrolysis and substrate specificity of a novel marine microbial carboxylesterase, E93.
Li Y; Rong Z; Li Z; Cui H; Li J; Xu XW
Front Microbiol; 2022; 13():1081094. PubMed ID: 36756200
[TBL] [Abstract][Full Text] [Related]
39. Irinotecan (CPT-11) metabolism and disposition in cancer patients.
Sparreboom A; de Jonge MJ; de Bruijn P; Brouwer E; Nooter K; Loos WJ; van Alphen RJ; Mathijssen RH; Stoter G; Verweij J
Clin Cancer Res; 1998 Nov; 4(11):2747-54. PubMed ID: 9829738
[TBL] [Abstract][Full Text] [Related]
40. Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene.
Wu MH; Chen P; Wu X; Liu W; Strom S; Das S; Cook EH; Rosner GL; Dolan ME
Pharmacogenetics; 2004 Sep; 14(9):595-605. PubMed ID: 15475733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
